Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer

202159 citationsJournal Articlehybrid Open Access

Authors

Yu Rebecca Miao · Stanford Medicine

Kaushik N. Thakkar · Stanford Medicine

Jin Qian · Stanford Medicine

Mihalis S. Kariolis · Stanford Medicine

Weitong Huang · HealthPartners

Saravanan Nandagopal · Stanford Medicine

Teddy Yang ·

Abstract

The data presented in this study provide justification for using a dual targeting, high-affinity sPD-1 receptor as an alternative to PD-1 or PD-L1 therapeutic antibodies for achieving superior therapeutic efficacy in cancers expressing both PD-L2 and PD-L1.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Immune Cell Function and Interaction CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 27, Issue 15, pp. 4435-4448

DOI: 10.1158/1078-0432.ccr-20-0482

Field-Weighted Citation Impact: 4.03